If you grade adverse events, the CTCAE v6.0 release is not a routine update. Here's what changed, what stayed the same, and where the highest-impact differences live.
If you grade adverse events in oncology trials, the CTCAE v6.0 release is the largest single change to the grading vocabulary in over a decade. This is Part 1 of a seven-part guide for coordinators, oncology nurses, and research operations leaders working through the transition right now.
We are writing this guide because we built a product on top of CTCAE v6.0 and had to ingest every change anyway. Sharing the work seemed more useful than keeping it.
What v6.0 actually is
CTCAE v6.0 is a structural revision, not a cosmetic one. The new release reorganizes terms across organ system classes, modifies grade definitions for many lab-based and symptom-based AEs, retires some terms, introduces new ones, and updates the MedDRA mapping to LLT codes aligned with MedDRA 28.0.
The headline number: more than 800 distinct criteria changes from v5.0. Some are clarifications. Some are real grade boundary shifts that will change how a clinical scenario gets graded. The hard part of the transition is that those two categories are not visually distinguishable in the NCI PDF, so every coordinator effectively has to retrain against the new criteria term-by-term.
The categories of change
Across the 800+ changes, the work falls into five buckets, in roughly descending order of how often you will encounter them:
-
Grade boundary shifts on common labs. Anemia, neutropenia, thrombocytopenia, and the standard hepatic and renal labs all received refinements. The boundaries that used to make a Grade 2 are not always the boundaries that make a Grade 2 in v6.0. Part 3 of this guide covers each one.
-
Symptom-based AE refinements. Fatigue, nausea, peripheral neuropathy, diarrhea, and the rest of the symptom panel received tighter functional impact language. The "interferes with ADL" boundary in particular is more precisely defined. Part 4 covers these.
-
Comorbidity and confounder language. v6.0 makes explicit what many sites were already doing implicitly: the criteria now reference pre-existing conditions and concurrent medications in places where attribution becomes ambiguous. This shows up most in the cardiac, hepatic, and neurologic systems.
-
New terms. A handful of immunotherapy-era and cell-therapy-era AEs are recognized as standalone terms rather than buried in "Other, specify." Cytokine release syndrome got more granular. Immune-mediated organ toxicities got dedicated entries.
-
Retired and renamed terms. A smaller set of v5.0 terms either no longer exist or have been folded into related canonical terms. The grading software at your site, your EDC, and your internal SOPs probably still reference the old names.
What did not change
Three things are worth saying explicitly:
- The 0 to 5 grade scale is unchanged. Grade 1 is still mild, Grade 5 is still fatal.
- The general definitions of each grade severity are unchanged at the meta level. What changes is the criteria that put a given AE at a given grade.
- Attribution to study drug is still a separate exercise from grading. v6.0 does not change how you decide whether the AE was related to treatment; it only changes how you decide what severity to assign.
This matters because some sites have framed the v6.0 transition as a complete re-learning. It is not. The grading framework is the same. The criteria within the framework have shifted, in some cases meaningfully.
What the transition actually costs
In practice, three operational costs show up at every site we've talked to:
-
Coordinator training time. Most sites are budgeting 4 to 8 hours per coordinator across the first month, then drift-correction sessions over the next quarter. The training itself is straightforward; the lookups during real grading sessions are what slow people down.
-
Concordance review on in-flight trials. Trials that started under v5.0 and are now transitioning create a discordance period where the same patient could plausibly be graded differently before and after the cutover. Most sites are handling this by tagging the version of CTCAE used at each visit and accepting the discontinuity, which is the FDA-recommended posture.
-
EDC and grading software updates. Every system that holds CTCAE pick-lists or criteria text needs to be updated. The big EDCs are shipping updates; smaller in-house tools tend to lag.
The hidden cost is the daily lookup tax: a coordinator who used to know v5.0 criteria from memory now has to verify against the PDF for every grading decision. That is the cost the lookup tool we built tries to eliminate.
How to use this guide
The remaining six parts of this guide each take one slice of the migration and go deep:
- Part 2: The 20 highest-impact changes for oncology coordinators.
- Part 3: Lab-based AE changes (anemia, neutropenia, thrombocytopenia, hepatic, renal).
- Part 4: Symptom-based AE changes (fatigue, nausea, peripheral neuropathy, diarrhea, rash).
- Part 5: Multi-drug attribution under v6.0.
- Part 6: A practical playbook for retraining your team.
- Part 7: The tools and references we recommend for the transition.
You can read them in order or jump straight to the topic you need. Each part is standalone and includes the relevant CTCAE term references and grade tables, so you can take what you need without reading the rest of the series.
If you have questions or want us to cover a specific term in a future part, reply to the newsletter or email hello@burna.ai. The series is shaped by the questions we get from working coordinators.
This is Part 1 of the Burna AI CTCAE v6.0 Migration Guide. Burna AI is the safety and data quality platform for oncology drug development, from clinical trials through postmarket surveillance.
